Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patients treated at Mayo Clinic. Our cohort received a median of eight prior lines of therapy. Six patients received belantamab in combination with other medications (pomalidomide, cyclophosphamide, thalidomide), 13 patients (36%) were 70 years or older, two patients had a creatinine of >2.5 mg/dL, and one patient was on dialysis. All three patients with renal failure received full dose belantamab. Chimeric antigen receptor (CAR-T) therapy was used prior to belantamab in seven patients and none of them responded to belantamab therapy. The overall response rate (ORR) was 33% (CR 6%, VGPR 8%, PR 19%), like the ORR reported in the DREAMM-2 trial. Keratopathy developed in 16 patients (43%), grade 1 in six patients, grade 2 in seven patients, and grade 3 in three patients. Eight percent discontinued therapy due to keratopathy. The median PFS and OS was 2 months and 6.5 months, respectively.

Belantamab mafodotin 是一种针对多发性骨髓瘤的高选择性靶向治疗。它针对浆细胞上的 B 细胞成熟抗原 (BCMA)，并在几项随机临床试验中显示出有希望的结果。我们报告了在梅奥诊所接受治疗的 36 名患者的结果。我们的队列接受了中位数的八线治疗。6 名患者接受 belantamab 联合其他药物（泊马度胺、环磷酰胺、沙利度胺），13 名患者（36%）年龄在 70 岁或以上，2 名患者肌酐>2.5 mg/dL，1 名患者正在透析。所有三名肾功能衰竭患者均接受全剂量 belantamab。7 名患者在 belantamab 之前使用了嵌合抗原受体 (CAR-T) 疗法，但没有一人对 belantamab 疗法有反应。总反应率 (ORR) 为 33% (CR 6%, VGPR 8%, PR 19%), 就像 DREAMM-2 试验中报告的 ORR。16 名患者（43%）出现角膜病变，6 名患者出现 1 级，7 名患者出现 2 级，3 名患者出现 3 级。8% 因角膜病变而停止治疗。中位 PFS 和 OS 分别为 2 个月和 6.5 个月。